Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract

Two mouse urokinase-type plasminogen activator receptor (muPAR) cDNAs were isolated: muPAR1 is homologous to the human urokinase-type plasminogen activator receptor while muPAR2 codes for a 199 residue protein sharing the first 133 residues with muPAR1. Mouse genomic DNA sequencing indicates that the two different mRNAs arise by alternative splicing. In situ hybridization showed differential expression of the two mRNAs in mouse gastric mucosa. muPAR1 mRNA is located in luminal epithelial cells situated close to urokinase-type plasminogen activator- producing connective tissue cells of the lamina propria, pointing to plasmin generation controlled by the cooperation of different cells that may play a role in the release of gastric epithelial cells. muPAR2 mRNA is expressed in the basal epithelial cells, and the deduced protein sequence includes the receptor ligand binding domain, but omits the region involved in glycolipid-mediated membrane anchoring, suggesting that muPAR2 may code for a secreted uPA binding protein.

[1]  K. Danø,et al.  Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus. , 2005, European Journal of Biochemistry.

[2]  F. Blasi,et al.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. , 1991, The American journal of pathology.

[3]  F. Blasi,et al.  The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. , 1991, The Journal of biological chemistry.

[4]  K. Danø,et al.  Localization of urokinase-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[5]  F. Blasi,et al.  Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. , 1991, The Journal of biological chemistry.

[6]  J. Cook,et al.  Serum transferrin receptor is a truncated form of tissue receptor. , 1990, The Journal of biological chemistry.

[7]  L. Orci,et al.  The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes , 1990, The Journal of cell biology.

[8]  K. Danø,et al.  Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. , 1990, The Journal of biological chemistry.

[9]  H. Earp,et al.  A truncated, secreted form of the epidermal growth factor receptor is encoded by an alternatively spliced transcript in normal rat tissue , 1990, Molecular and cellular biology.

[10]  L. Lund,et al.  Urokinase-type plasminogen activator is increased in the involuting ventral prostate of castrated rats. , 1990, Endocrinology.

[11]  E. Appella,et al.  The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. , 1990, The Journal of biological chemistry.

[12]  E. Appella,et al.  Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. , 1990, The EMBO journal.

[13]  S. Stacey,et al.  Plasminogen activator inhibitors: hormonally regulated serpins , 1990, Molecular and Cellular Endocrinology.

[14]  D. Belin,et al.  Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos , 1989, The Journal of cell biology.

[15]  J. Logan,et al.  The growth hormone-binding protein in rat serum is an alternatively spliced form of the rat growth hormone receptor. , 1989, Genes & development.

[16]  A. Vaheri,et al.  Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants , 1989, The Journal of cell biology.

[17]  S. Williams,et al.  Analysis of the signal for attachment of a glycophospholipid membrane anchor , 1989, The Journal of cell biology.

[18]  M. Scully,et al.  Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. , 1989, The Journal of biological chemistry.

[19]  D. Belin,et al.  Characterization of the cellular binding site for the urokinase-type plasminogen activator. , 1989, The Journal of biological chemistry.

[20]  F. Walsh,et al.  Alternative splicing generates a secreted form of N-CAM in muscle and brain , 1988, Cell.

[21]  B. Cullen,et al.  COOH-terminal requirements for the correct processing of a phosphatidylinositol-glycan anchored membrane protein. , 1988, The Journal of biological chemistry.

[22]  D. Loskutoff,et al.  Fibrinolytic System of Vascular Endothelial Cells , 1988 .

[23]  V Ottevanger,et al.  Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. , 1988, The Journal of investigative dermatology.

[24]  J. Baker,et al.  Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin , 1988, The Journal of cell biology.

[25]  K. Rock,et al.  Cloning and expression of a cDNA for the T-cell-activating protein TAP. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[26]  F. Blasi.  Surface Receptors for Urokinase Plasminogen Activator , 1988 .

[27]  S. Udenfriend,et al.  Aspartic acid-484 of nascent placental alkaline phosphatase condenses with a phosphatidylinositol glycan to become the carboxyl terminus of the mature enzyme. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[28]  F. Blasi,et al.  A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. , 1988, The Journal of biological chemistry.

[29]  A. Vaheri,et al.  Ultrastructural localization of plasma membrane-associated urokinase- type plasminogen activator at focal contacts , 1988, The Journal of cell biology.

[30]  F. Dumont,et al.  N-terminal and cDNA characterization of murine lymphocyte antigen Ly-6C.2. , 1988, Journal of immunology.

[31]  D. Belin,et al.  Plasminogen activator and mouse spermatozoa: urokinase synthesis in the male genital tract and binding of the enzyme to the sperm cell surface , 1987, The Journal of cell biology.

[32]  F. Blasi,et al.  Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors , 1987, The Journal of cell biology.

[33]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[34]  A. Bothwell,et al.  Isolation of a murine Ly‐6 cDNA reveals a new multigene family. , 1986, EMBO Journal.

[35]  J. Plescia,et al.  The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type , 1986, The Journal of cell biology.

[36]  D. Rifkin,et al.  Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade , 1986, Cell.

[37]  R. W. Scott,et al.  Inhibition of tumor-cell-mediated extracellular matrix destruction by a fibroblast proteinase inhibitor, protease nexin I. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Corti,et al.  Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D. Belin,et al.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase , 1985, The Journal of cell biology.

[40]  K. Danø,et al.  Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse , 1984, The Journal of cell biology.

[41]  J. Devereux,et al.  A comprehensive set of sequence analysis programs for the VAX , 1984, Nucleic Acids Res..

[42]  L. Ossowski,et al.  Antibodies to plasminogen activator inhibit human tumor metastasis , 1983, Cell.

[43]  K. Danø,et al.  Purification and characterization of a plasminogen activator from mouse cells transformed by an oncogenic virus. , 1980, Biochimica et biophysica acta.

[44]  L. Ossowski,et al.  Mammary plasminogen activator: correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue , 1979, Cell.

[45]  T. Gelehrter,et al.  Mechanism of dexamethasone inhibition of plasminogen activator in rat hepatoma cells. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[46]  K. Danø,et al.  Serine enzymes released by cultured neoplastic cells , 1978, The Journal of experimental medicine.

[47]  S. Strickland,et al.  Plasminogen activator in early embryogenesis: Enzyme production by trophoblast and parietal endoderm , 1976, Cell.

[48]  L. Kirkeby,et al.  Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. , 1991, The American journal of pathology.

[49]  D. Rifkin,et al.  Cell-associated plasminogen activation: regulation and physiological functions. , 1988, Annual review of cell biology.

[50]  M. Ferguson,et al.  Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures. , 1988, Annual review of biochemistry.

[51]  B. Nadal-Ginard,et al.  Alternative splicing: a ubiquitous mechanism for the generation of multiple protein isoforms from single genes. , 1987, Annual review of biochemistry.

[52]  E. Appella,et al.  The Receptor-Binding Sequence of Urokinase , 1987 .

[53]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[54]  E. Reich.  ACTIVATION OF PLASMINOGEN: A GENERAL MECHANISM FOR PRODUCING LOCALIZED EXTRACELLULAR PROTEOLYSIS , 1978 .